HemaCare Corp., a provider of human blood and immune cells for medical therapies and research based in Northridge, has expanded its product line to include special types of bone marrow.
According to a statement from the company on Tuesday, bone marrow is difficult to procure due to cell versatility, an invasive collection procedure and limited access to qualified suppliers. But as therapies move from pre-clinical to clinical development, starting materials such as bone marrow is needed.
“Bone marrow-derived cell therapy starting materials are being used to support the development of a wide variety of new cell and gene therapies,” Dr. Dominic Clarke, global head of cell therapy at HemaCare, said in a statement. “Launching HemaCare’s GMPrime bone marrow aspirate ensures the industry experiences a smoother transition from research to process development through to commercialization.”
Shares of HemaCare (HEMA) closed Tuesday up 10 cents, or a fraction of a percent, to $19.75 on the over-the-counter market.